Reversing Fatty Liver Disease with Common Drugs
Researchers at the University of Barcelona have discovered that combining pemafibrate and telmisartan can significantly reduce liver fat and cardiovascular risks in models of metabolic dysfunction-associated steatotic liver disease (MASLD).
This condition, which affects roughly one in three adults, occurs when excess fat builds up inside liver cells, leading to serious liver damage and a higher risk of death from cardiovascular disease.
The drug duo works better together than alone, likely due to complementary mechanisms.
The study, published in Pharmacological Research, also uncovered a new role for the PCK1 protein in fat metabolism, offering a promising approach to treating this widespread liver disorder.
Author's summary: Two drugs reduce liver fat and cardiovascular risks.
Key findings include:
- Combining pemafibrate and telmisartan reduces liver fat and cardiovascular risks in MASLD models.
- The drug combination works better together than alone due to complementary mechanisms.
- A new role for the PCK1 protein in fat metabolism was discovered.